For the second quarter of 2026, analysts anticipate Incyte to report consensus revenue of $1.40 billion and an adjusted EPS of $1.61, while the stock currently trades at approximately $117.67 against an average price target of $114.55.
The central focus for investors remains the commercial performance of Opzelura and its ability to diversify revenue streams ahead of the looming 2028 Jakafi patent cliff.
Recent quarterly results showed strong demand for Incyte’s core oncology franchise, although Opzelura sales have faced scrutiny for occasionally trailing elevated street estimates despite consistent double-digit growth. Management has reaffirmed full-year guidance as the company advances high-impact Phase 3 programs like povorcitinib to ensure a sustainable growth trajectory.